Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07500207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2026 (before its estimated May 25, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group
Trial Details
NCT Number NCT07500207
Lead Sponsor Changchun BCHT Biotechnology Co.
Conditions
(from sponsor)		 Rabies Prevention
Enrollment 3,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov